Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

The RetinalGeniX™ imaging system is designed to allow routine screenings to be conducted by general practitioners, optometric technicians, clinics, etc., giving highly specialized ophthalmologists and ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China.

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

February 20, 2025, Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared ...

Celonic Group, a “Pure Play” biologics contract development and manufacturing organization (CDMO), has signed a multi-year ...